Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Hypertension, Dyslipidemia, Diabetes
Phase NA
Enrollment 8252
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for the integrated management of hypertension, dyslipidemia, and type 2 diabetes among adults aged 50 to 75 years without prior cardiovascular disease in China. The trial will evaluate whether a fixed-dose combination strategy improves the 10-year cardiovascular disease risk estimated using the PREVENT equations at Phase 1. Participants will be further followed to determine whether the fixed-dose combination strategy reduces major cardiovascular events and improves cognitive outcomes compared with usual care at Phase 2.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Fixed-Dose Combination Strategy — Participants assigned to the intervention group will receive a fixed-dose combination strategy for the integrated control of blood pressure, lipid, and glucose. Eight prespecified fixed-dose formulations will be used, differing in antihypertensive intensity and rosuvastatin dose. All formulations will include olmesartan medoxomil/amlodipine, rosuvastatin, ezetimibe 10 mg, and dapagliflozin 10 mg, with indapamide 2.5 mg included in selected formulations. The olmesartan medoxomil/amlodipine dose will range from 5/1.25 mg to 20/5 mg, and the rosuvastatin dose will be either 5 mg or 10 mg. Treatment will be selected and adjusted among the prespecified fixed-dose formulations according to participants' blood pressure levels, treatment targets, tolerability, and safety. If the prespecified blood pressure, lipid, or glycemic targets are not achieved despite the highest fixed-dose regimen, additional open-label medications may be prescribed according to guideline recommendations.

Primary Outcomes

  • 10-year CVD risk (12 months)
  • Composite cardiovascular disease outcome (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-11
Completion: 2030-03-01
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 8252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China Medical University, China
Contact Information
Study Contact:
Xincan Liu
+86 13203825657
Liuxincan103@163.com
The First Affiliated Hospital of Henan University of Chinese Medicine
Xuchen Han
+86 15504766986
hanxuchen2004@163.com
Affiliated Hospital of Chifeng University
Kai Zheng
+86 15004963990
udbmnm2012@163.com
Tongliao People's Hospital
Interventions
  • Drug: Fixed-Dose Combination Strategy — Participants assigned to the intervention group will receive a fixed-dose combination strategy for the integrated control of blood pressure, lipid, and glucose. Eight prespecified fixed-dose formulations will be used, differing in antihypertensive intensity and rosuvastatin dose. All formulations will include olmesartan medoxomil/amlodipine, rosuvastatin, ezetimibe 10 mg, and dapagliflozin 10 mg, with indapamide 2.5 mg included in selected formulations. The olmesartan medoxomil/amlodipine dose will range from 5/1.25 mg to 20/5 mg, and the rosuvastatin dose will be either 5 mg or 10 mg. Treatment will be selected and adjusted among the prespecified fixed-dose formulations according to participants' blood pressure levels, treatment targets, tolerability, and safety. If the prespecified blood pressure, lipid, or glycemic targets are not achieved despite the highest fixed-dose regimen, additional open-label medications may be prescribed according to guideline recommendations.
Study Locations (15 sites)
The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan China
Affiliated Hospital of Chifeng University, Chifeng, Inner Mongolia China
Tongliao People's Hospital, Tongliao, Inner Mongolia China
Kunshan Hospital of Chinese Medicine, Kunshan, Jiangsu China
Suzhou Wujiang District Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu China
The Fifth People's Hospital of Wujiang District, Suzhou, Jiangsu China
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu China
Taixing Second People's Hospital, Taizhou, Jiangsu China
Central Hospital of Jinzhou, Jinzhou, Liaoning China
Panjin Central Hospital, Panjin, Liaoning China
Eligibility Criteria
Inclusion Criteria: * Men or women * Age ≥50 years and \<75 years * Systolic blood pressure ≥130 mmHg * LDL-C ≥1.8 mmol/L (70 mg/dL) * Type 2 diabetes with HbA1c ≥6.5% and \<12% * Willing to participate and able to sign informed consent Exclusion Criteria: * Known secondary cause of hypertension * Type 1 diabetes * Pancreatic insufficiency or diabetes secondary to pancreatitis * Triglycerides ≥5.65 mmol/L (500 mg/dL) * History of myocardial infarction, stroke, or heart failure * History of coronary, cerebrovascular, or peripheral arterial revascularization * Abnormal kidney function, defined as estimated glomerular filtration rate \<30 mL/min/1.73 m² or dialysis * Abnormal liver function, defined as alanine aminotransferase or aspartate aminotransferase \>3 times the upper limit of normal * Abnormal serum potassium, defined as serum potassium \>5.5 mmol/L or \<3.5 mmol/L * Contraindication to any of the components of the polypill * Currently living with another PACIF participant * Pregnancy, currently trying to become pregnant, or of child-bearing potential and not using birth control * Clinical diagnosis of dementia or treatment with medications for dementia * History of malignancy * Life expectancy \<3 years * Currently participating in another intervention study * Any factors judged by the clinic team to be likely to limit adherence to interventions
Conditions Radiation-Induced Skin Injury
Phase PHASE1
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, open-label, Phase I single-arm clinical trial evaluating the safety and tolerability of a topical AKK probiotic preparation (Akkermansia muciniphila) for the prevention and treatment of radiation-induced skin injury in patients receiving radiotherapy for breast cancer, head and neck cancer (including nasopharyngeal carcinoma). A total of 40 participants are planned to receive the AKK preparation applied to the radiation field three times daily, starting one day before the first radiotherapy fraction and continuing until 14 days after the last fraction. The primary outcome is the incidence of grade ≥2 acute radiation dermatitis (ARD) assessed by RTOG and CTCAE criteria. Secondary outcomes include changes in skin micro-features under digital dermoscopy, skin microbiota composition, quality of life (Skindex-16), and safety.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Biological: AKK Topical Preparation — Inactivated whole-cell Akkermansia muciniphila topical preparation. Dose: 140 µL per 25 cm² of radiation field (7 × 10⁷ CFU). Applied three times daily: once 1 hour before each radiotherapy fraction, and twice at other times (e.g., afternoon and bedtime). Treatment begins one day before the first radiotherapy fraction (after baseline skin sampling) and continues until 14 days after the last radiotherapy fraction.

Primary Outcomes

  • Incidence of Grade ≥2 Acute Radiation Dermatitis (From first radiotherapy fraction up to 90 days after the last fraction)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-07
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: West China Hospital
Collaborators: West China-Jintang Hospital, Sichuan University
Contact Information
Study Contact:
Xuelei Ma
+8613408410416
drmaxuelei@gmail.com
West China Hospital of Sichuan University
Lei Zhang
+8618908070191
314189929@qq.com
Jintang County First People's Hospital
Interventions
  • Biological: AKK Topical Preparation — Inactivated whole-cell Akkermansia muciniphila topical preparation. Dose: 140 µL per 25 cm² of radiation field (7 × 10⁷ CFU). Applied three times daily: once 1 hour before each radiotherapy fraction, and twice at other times (e.g., afternoon and bedtime). Treatment begins one day before the first radiotherapy fraction (after baseline skin sampling) and continues until 14 days after the last radiotherapy fraction.
Study Locations (2 sites)
West China Hospital of Sichuan University, Chengdu, Sichuan 610041 China
Jintang County First People's Hospital, Chengdu, Sichuan 610400 China
Eligibility Criteria
Inclusion Criteria: * Diagnosis of breast cancer, head and neck cancer (including nasopharyngeal carcinoma) receiving radiotherapy * Age ≥18 years and ≤75 years, any sex * Signed written informed consent * Radiation field skin area can be localized and skin inflammation can be assessed * ECOG performance status 0-1, life expectancy ≥3 months * Adequate major organ function * Fertile patients (both sexes) must use effective medical contraception during the study and for 6 months after the last dose * Willing to comply with follow-up and skin image collection Exclusion Criteria: * Cognitive impairment preventing understanding of the study * Use of antibiotics or antifungals within 1 month * Previous treatment with other bacterial preparations * Participation in other bacterial therapy trials * Any abnormality (e.g., scar, tattoo) in the radiation field that would interfere with assessment * Allergy to probiotics or any component of the study preparation; history of severe allergic reactions (e.g., anaphylaxis, angioedema, respiratory distress, allergic purpura, Arthus reaction) * Use of immunosuppressive drugs * Symptomatic or rapidly progressive central nervous system metastases, extensive lung metastases causing dyspnea, tumor invading major vessels or nerves * Poorly controlled cardiac disease (NYHA class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, clinically significant arrhythmia requiring treatment) * Pregnancy or breastfeeding * Active tuberculosis, bacterial or fungal infection (grade ≥2 per CTCAE), or HIV infection * Substance abuse or psychiatric disorder * Active autoimmune disease or history thereof (exceptions: vitiligo, childhood asthma fully resolved with no intervention in adulthood) * History of alcohol or drug abuse * Planned pregnancy from screening until 12 months after last treatment * Any concomitant condition that, in the investigator's judgment, would compromise patient safety or study completion * Any other condition deemed unsuitable for enrollment by the investigator * Inability to provide written informed consent
Conditions Fuchs Endothelial Corneal Dysfunction, O...
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall goal of this study is to develop Brillouin microscope as a novel tool for measuring biomechanical and hydration properties of human tissues in vivo.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Number of subjects to successfully complete Brillouin measurement without serious unanticipated adverse events related to application of the device. (Through completion of the single study visit, approximately 1-2 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-08-18
Completion: 2027-09-01
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Massachusetts Eye and Ear Infirmary, National Eye Institute (NEI)
Principal Investigators:
  • Seok-Hyun Yun, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Brigham
Contact Information
Study Contact:
Soyeon (Selina) Ahn, PhD
3396009736
sahn14@mgh.harvard.edu
Seok-Hyun Yun, PhD
6177688704
syun@mgh.harvard.edu
Soyeon (Selina) Ahn, PhD
3396009736
sahn14@mgh.harvard.edu
Massachusetts General Brigham
Interventions
N/A
Study Locations (1 sites)
Massachusetts General Brigham, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * Healthy volunteers with normal eyes * Visual acuity between +2 to -6 diopters Exclusion Criteria: * History of refractive or cataract surgery * History of ocular disease * Active non-ophthalmic systemic disease
Conditions Advanced ALK/ROS1-positive NSCLC, Carcin...
Phase Not Applicable
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients with non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements. Lorlatinib is a highly effective third-generation tyrosine kinase inhibitor, but it causes neuropsychological adverse events (NAEs) in approximately 42% of patients, including cognitive impairment, mood changes, and speech disturbances. Vortioxetine has demonstrated cognitive improvement in depressed patients and in preclinical models of androgen deprivation therapy-induced cognitive impairment. Twenty-four adult patients with ALK/ROS1-positive NSCLC receiving lorlatinib as standard care and prescribed vortioxetine (10-20 mg/day) for NAE management will be enrolled. Comprehensive neuropsychological assessments and quality-of-life questionnaires will be conducted at baseline, week 6, week 12, and month 6 to document changes in cognitive function, depressive symptoms, and quality of life.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Psychomotor Speed (Baseline, Week 6, Week 12)
  • Processing Speed and Visual Attention (Baseline, Week 6, Week 12)
  • Executive Function and Cognitive Flexibility (Baseline, Week 6, Week 12)
  • Selective and Sustained Attention (Baseline, Week 6, Week 12)
  • Working Memory (Baseline, Week 6, Week 12)
  • Processing Speed (Baseline, Week 6, Week 12)
  • Verbal Learning and Memory (Baseline, Week 6, Week 12)
  • Language (Baseline, Week 6, Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-10
Completion: 2027-11-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Contact Information
Study Contact:
Felipe Canro, MD
+57 310 8593083
felipe.canro@gmail.com
LIliana Gutierrez, RN, MSc
+573003768158
lgutierrez@fctic.org
Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo CTIC
Interventions
N/A
Study Locations (1 sites)
Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo CTIC, Bogotá, 110131 Colombia
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of ALK/ROS1-positive non-small cell lung cancer (NSCLC), stage IIIB/IV. * Currently receiving lorlatinib as part of the standard therapeutic regimen. * Documented neurocognitive adverse events (NAEs) attributable to lorlatinib. * Age \>= 18 years. * ECOG performance status 0-2. * Ability to understand and sign informed consent. * Expected survival \>= 6 months. * Planned initiation of vortioxetine as part of standard care. * Ability to complete neuropsychological tests and questionnaires in Spanish. Exclusion Criteria: * Prior diagnosis of major cognitive impairment unrelated to cancer treatment. * Current use of another antidepressant that cannot be discontinued. * Uncontrolled major psychiatric disorder. * History of uncontrolled epilepsy or recent seizures. * Severe hepatic or renal impairment. * Known hypersensitivity to vortioxetine. * Participation in another clinical trial within the past 30 days. * Inability to provide informed consent. * Life expectancy \< 3 months. * Contraindications to vortioxetine (e.g., concomitant MAOI use). * Prior vortioxetine use. * Severe psychiatric disorders or significant cognitive impairment unrelated to lorlatinib.
Conditions Safety in Asthma Patients
Phase PHASE1
Enrollment 40
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase 1 study, randomized, double-blind, placebo-controlled, 2 treatment, 2 period crossover study to evaluate the pharmacokinetics, safety, and tolerability of a single inhaled dose of ASY202 in adults with stable asthma. Following screening, eligible participants will be enrolled and randomized to one of two treatment sequences. Participants will receive a single inhaled dose of ASY202 and a single inhaled dose of placebo, each administered once during separate study periods. During each treatment period, subjects will stay in the clinical research unit for safety monitoring and PK assessments, including serial blood sampling, spirometry, vital signs, clinical laboratory tests, and ECGs. Each period will include post dose assessments for up to 24 hours. Participants will return for their next treatment period after a washout interval to ensure complete clearance of study medication. All subjects will receive both treatments over the course of the study. A follow-up visit will occur after the last dose to assess ongoing safety and tolerability.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Combination Product: ASY202 — ASY202 is a pre-metered drug-device combination product containing a dry-powder formulation of dihydroergotamine (DHE) intended for oral inhalation, delivered via a dry powder inhaler (DPI).
  • Combination Product: Placebo — Placebo inhalation powder delivered via a dry powder inhaler (DPI) device.

Primary Outcomes

  • Effect of a single dose of ASY202 2 mg compared with placebo on pulmonary function in adults with asthma. (Post dose 5 minutes, 15 minutes, 40 minutes, 1hour, 2 hours and 4 hours.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-05-26
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aspeya, Inc.
Contact Information
Study Contact:
Guillaume Crespel
+ 41 78 688 05 43
clinicaltrials@aspeya.com
Amina Z. Haggag, Dr.
714-774-7777
a.haggag@cenexel.com
CenExel- Anaheim Clinical trials LLC
Amina Z. Haggag, Dr.
CenExel- Anaheim Clinical trials LLC
Interventions
  • Combination Product: ASY202 — ASY202 is a pre-metered drug-device combination product containing a dry-powder formulation of dihydroergotamine (DHE) intended for oral inhalation, delivered via a dry powder inhaler (DPI).
  • Combination Product: Placebo — Placebo inhalation powder delivered via a dry powder inhaler (DPI) device.
Study Locations (3 sites)
Sun City Clinical Research, Glendale, Arizona 85304 United States
CenExel- Anaheim Clinical trials LLC, Anaheim, California 92801 United States
Worldwide Clinical Trials- Early Phase Research Unit, San Antonio, Texas 78217 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-55 years * Diagnosed asthma * Stable asthma treatment * Non smoker * BMI 18.5-35 kg/m² * Women of childbearing potential and men agree to use acceptable contraception Exclusion Criteria: * Asthma exacerbation requiring systemic steroids, ER visit, or hospitalization within 3 months * Respiratory tract infection within 4 weeks prior to screening * Use of oral or IV corticosteroids * Use of prohibited medications (e.g., CYP3A4 modulators, triptans, vasoconstrictors, QT prolongers, theophylline, systemic steroids) * Other lung diseases (e.g., Chronic Obstructive Pulmonary Disease (COPD)) or conditions interfering with spirometry * Unstable asthma or unresolved safety concerns before dosing * Clinically significant cardiovascular disease or ECG abnormalities contraindicating DHE * Three or more risk factors for Coronary Artery Disease (CAD) (hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, females who are surgically or physiologically postmenopausal, or males who are over 40 years of age) * Pregnancy, breastfeeding, or unwillingness to use required contraception
Conditions Pancreatectomy, Diabetes Mellitus Type 2...
Phase Not Applicable
Enrollment 579
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time. The study will include adults without diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS. Researchers will study whether participants develop diabetes after surgery and whether this risk changes according to the type of pancreatic resection. Information from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Incidence of New-Onset Diabetes Mellitus After Pancreatectomy (Within 12 months after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-07-20
Completion: 2041-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 579 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators: European Foundation for the Study of Diabetes
Principal Investigators:
  • Teresa Mezza (PRINCIPAL_INVESTIGATOR) - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Information
Study Contact:
Teresa Mezza, MD, PhD
06 30156664
teresa.mezza@policlinicogemelli.it
Teresa Mezza, MD, PhD
0630156664
teresa.mezza@policlinicogemelli.it
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Interventions
N/A
Study Locations (1 sites)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168 Italy
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥18 years) * No diabetes mellitus at baseline * Undergoing partial, near-total, or total pancreatectomy at the study center * Availability of clinical and metabolic data according to study component * Written informed consent for the prospective component Exclusion Criteria: * Diabetes mellitus at baseline * Age \<18 years * Missing key clinical data precluding eligibility assessment or primary outcome evaluation * Refusal or inability to provide informed consent for the prospective component, where applicable
Conditions Treatment-resistant Depression (TRD), Ma...
Phase NA
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Treatment-resistant depression (TRD) is a major clinical challenge affecting a substantial proportion of patients with major depressive disorder who do not adequately respond to conventional antidepressant treatments. Intermittent theta burst stimulation (iTBS), a non-invasive neuromodulation technique targeting the left dorsolateral prefrontal cortex, has emerged as an effective treatment option for these patients. However, the biological mechanisms underlying treatment response remain poorly understood. This single-center, prospective, investigator-initiated clinical study aims to investigate the effects of iTBS on clinical symptoms, executive functions, and peripheral inflammatory and neuroprotective biomarkers in patients with treatment-resistant depression. Fifty patients with treatment-resistant depression and fifty healthy control participants will be enrolled. Patients will receive active iTBS treatment for four weeks (20 sessions), while healthy controls will undergo baseline clinical, cognitive, and biological assessments without receiving any intervention. Clinical outcomes will be evaluated using the 17-item Hamilton Depression Rating Scale (HAM-D-17), Patient Health Questionnaire-9 (PHQ-9), Clinical Global Impression (CGI), and Insomnia Severity Index (ISI). Executive functions will be assessed using the Wisconsin Card Sorting Test, Trail Making Test A and B, and verbal fluency tests. Peripheral blood samples will be collected before and after treatment to measure inflammatory, neuroplasticity, and neuroprotective biomarkers, including IL-1β, IL-6, IL-10, TNF-α, high-sensitivity C-reactive protein (hs-CRP), brain-derived neurotrophic factor (BDNF), apolipoprotein D (APOD), serum amyloid A1 (SAA1), and serum amyloid A2 (SAA2). Gene expression analyses will also be performed using quantitative polymerase chain reaction (qPCR). The study aims to identify biological mechanisms associated with iTBS treatment response and to explore potential biomarkers that may predict clinical improvement in patients with treatment-resistant depression. The findings may contribute to the development of personalized neuromodulation strategies and biomarker-guided treatment approaches for depression.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Intermittent Theta Burst Stimulation (iTBS) — Intermittent theta burst stimulation (iTBS) will be administered over the left dorsolateral prefrontal cortex using a CE-marked MagVenture X100 transcranial magnetic stimulation device. Stimulation intensity will be set at 90% of each participant's resting motor threshold. The protocol will consist of bursts of three pulses delivered at 50 Hz, repeated at a frequency of 5 Hz, with 2-second stimulation trains followed by 8-second intertrain intervals. Participants will receive 1800 pulses per session, five sessions per week, for a total of 20 sessions over four weeks (36,000 pulses in total). Participants will continue their routine pharmacological treatments throughout the study, and no investigational medicinal products will be initiated as part of the research protocol.

Primary Outcomes

  • Change in Hamilton Depression Rating Scale (HAM-D-17) Total Score (Baseline and Week 4)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-01
Completion: 2027-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gulhane Training and Research Hospital
Contact Information
Study Contact:
BEYAZIT GARİP, Principal Investigator
+903123044512
beyazitgarip@gmail.com
BEYAZIT GARİP, Principal Investigator
03123044512
beyazitgarip@gmail.com
Gulhane Training and Research Hospital
Dr.Beyazıt Garip
03122977975
beyazitgarip@gmail.com
Gulhane Training and Research Hospital
Interventions
  • Device: Intermittent Theta Burst Stimulation (iTBS) — Intermittent theta burst stimulation (iTBS) will be administered over the left dorsolateral prefrontal cortex using a CE-marked MagVenture X100 transcranial magnetic stimulation device. Stimulation intensity will be set at 90% of each participant's resting motor threshold. The protocol will consist of bursts of three pulses delivered at 50 Hz, repeated at a frequency of 5 Hz, with 2-second stimulation trains followed by 8-second intertrain intervals. Participants will receive 1800 pulses per session, five sessions per week, for a total of 20 sessions over four weeks (36,000 pulses in total). Participants will continue their routine pharmacological treatments throughout the study, and no investigational medicinal products will be initiated as part of the research protocol.
Study Locations (2 sites)
Gulhane Training and Research Hospital, Ankara, Ankara 06000 Turkey (Türkiye)
Gulhane Training and Research Hospital, Ankara, 06000 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria Treatment-Resistant Depression Group: Age between 18 and 55 years. Male or female participants. Diagnosis of Major Depressive Disorder according to DSM-5-TR criteria. Inadequate response to at least two antidepressant treatments administered at adequate doses and durations. Eligible for transcranial magnetic stimulation (TMS) treatment. Able and willing to provide written informed consent. Able to complete neuropsychological assessments. Able to attend study visits and complete the treatment protocol. Healthy Control Group: Age between 18 and 55 years. Male or female participants. No current DSM-5-TR psychiatric disorder. Able and willing to provide written informed consent. Able to complete neuropsychological assessments. Exclusion Criteria Schizophrenia, bipolar disorder, organic mental disorders, or other major psychiatric disorders. History of epilepsy, brain tumor, severe head trauma, or significant neurological disease. Any contraindication to TMS. Presence of intracranial metal implants, cardiac pacemakers, cochlear implants, or other incompatible implanted devices. Active infection. Autoimmune disease or chronic inflammatory disease. Electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation within the previous 5 years. Previous intravenous or intranasal ketamine treatment. Pregnancy or breastfeeding. Active alcohol or substance use disorder. Inability to comply with study procedures. Inability to tolerate the iTBS protocol. Withdrawal of informed consent at any stage of the study.
Conditions Bipolar Disorder (BD), Bipolar 1 Depress...
Phase PHASE4
Enrollment 62
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is exploring a new approach to treating depression in people with bipolar disorder (BD). Investigators are testing whether a non-invasive form of brain stimulation can help us understand depressed-to-euthymic mood shifts and their related brain circuits in BD. Investigators in this study will use a technique called repetitive transcranial magnetic stimulation, or rTMS. It uses non-invasive magnetic pulses delivered to the scalp to stimulate specific areas of the brain. rTMS is already used to treat depression, and investigators are now studying whether it can be made even more effective for people with bipolar disorder by precisely targeting an individualized brain region for each participant. Participants in this study will receive two courses of rTMS, one active and one placebo (called "sham"), in a randomized order so investigators can directly compare the effects. Before treatment, investigators will use brain scans (MRI) to create a personalized map of each participant's brain activity. This lets investigators identify the exact stimulation target most likely to influence the brain circuits involved in BD mood shifts. Investigators will track mood symptoms closely throughout the study to measure what changes. Investigators believe that depression in BD is partly driven by disrupted communication between two brain regions involved in processing what feels important or rewarding. Investigators want to find out whether rTMS can restore that communication and whether doing so leads to measurable improvements in depression.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: MagVenture MagPro TMS system — TANS-guided SAL Acc iTBS approach: Targeted Functional Network Stimulation (TANS) combines precision functional mapping (PFM) with electric field (E-field) modeling to individualize circuit targeting. Active rTMS will be intermittent theta burst simulation (iTBS) delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly active rTMS sessions).
  • Device: Sham Stimulation — An Active/Placebo (A/P) sham TMS coil will be used to deliver placebo stimulation. The A/P coil is a double-sided coil in which one side delivers effective magnetic stimulation, while the opposite side is configured to produce a sham condition without inducing cortical activation. Sham stimulation will also be delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly sham rTMS sessions).

Primary Outcomes

  • Change from Baseline to 1-Week Post-rTMS in Montgomery-Asberg Depression Rating Scale (MADRS) Score (Baseline to 1-week post-rTMS)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-03
Completion: 2031-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 62 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: BD2 LLC
Principal Investigators:
  • Immanuel Elbau, MD, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Research Coordinator, Interventional Psychiatry Program
646-962-2900
tmsinfo@med.cornell.edu
Research Coordinator, Interventional Psychiatry Program
646-962-2900
tmsinfo@med.cornell.edu
Weill Cornell Medicine
Immanuel Elbau, MD, PhD
Weill Cornell Medicine
Interventions
  • Device: MagVenture MagPro TMS system — TANS-guided SAL Acc iTBS approach: Targeted Functional Network Stimulation (TANS) combines precision functional mapping (PFM) with electric field (E-field) modeling to individualize circuit targeting. Active rTMS will be intermittent theta burst simulation (iTBS) delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly active rTMS sessions).
  • Device: Sham Stimulation — An Active/Placebo (A/P) sham TMS coil will be used to deliver placebo stimulation. The A/P coil is a double-sided coil in which one side delivers effective magnetic stimulation, while the opposite side is configured to produce a sham condition without inducing cortical activation. Sham stimulation will also be delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly sham rTMS sessions).
Study Locations (1 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Adults of all genders aged 18-70 at the time of screening. 3. Diagnosis of Bipolar Disorder (by DSM-V criteria) 4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \>= 14 or as determined by expert clinician). 5. Not currently taking medications for BD OR on a stable dose of medication for at least 1 month prior to screening and plans to remain off medications OR on this stable dose for the duration of participation. 6. Access to psychiatric care before, during, and after completion of the study. 7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation. 8. Proficiency in English sufficient to complete assessments and follow study procedure instructions. 9. Stated willingness to comply with all study procedures and availability for the duration of the study. Exclusion Criteria: 1. Imminent risk of suicide. 2. Presence of a primary DSM-5 diagnosis other than bipolar disorder (BD-I or BD-II), or a current comorbid psychiatric disorder that, in the opinion of the investigators, would confound outcome assessment or interfere with safe participation. 3. History of seizures or any condition / concurrent medication that could notably lower seizure threshold. 4. Met criteria for any significant substance use disorder (by DSM-V criteria) in the 6 months prior to screening. 5. History or presence of significant neurological disorder (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy). 6. History or presence of significant heart condition (e.g., recent myocardial infarction, congestive heart failure \> stage 2, angina pectoris, bradycardia or tachycardia at the baseline assessment, uncontrolled hypertension). 7. MRI contraindication, including presence of foreign metal bodies or implants, implanted or conductive objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), permanent make-up. 8. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation. 9. Abnormal bloodwork for electrolytes, thyroid, or liver function. 10. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures.
Conditions Resilience, Anxiety, Depressive Symptom,...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pilot randomised controlled trial is to examine the effects of a mindfulness-based music breathing intervention in enhancing resilience (primary outcome), and in reducing anxiety, depressive symptoms, loneliness, and improving health-related quality of life (secondary outcomes) among community-dwelling older adults at risk of mental health problems. It is hypothesised that compared with the control group, participants in the intervention group will report enhanced resilience, reduced anxiety, depressive symptoms, and loneliness, and improved health-related quality of life immediately post-intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Mindfulness-based music breathing intervention — Participants in the intervention group will receive a 4-week music plus mindfulness-based breathing program, consisting of one 60-minute face-to-face session per week. The sessions will be delivered in small groups by a qualified music breathing practitioner. The intervention will follow a structured protocol developed by the research team and reviewed by a certified trained music-breathing therapist. Each session will consist of four progressive breathing phases, including: I. Discovery Breathing - to increase awareness of breath and bodily sensations II. Triangular Breathing - to cultivate control and balance through rhythm III. Silent Breathing - to promote stillness and internal reflection IV. Music Breathing - to combine guided music listening with mindful breathing for emotional regulation
  • Behavioral: control group — Participants in the control group will receive usual care, which may include access to existing community-based services, health education, or leisure activities, but will not involve any structured music or mindfulness-based intervention.

Primary Outcomes

  • Resilience (Change from baseline to post-intervention (at 4-week follow-up).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-08
Completion: 2026-08-31
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Ankie Tan Cheung, PhD, MPhil, BN (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
Ankie Tan Cheung, PhD, MPhil, BN
+852 39430515
ankiecheung@cuhk.edu.hk
Ankie Tan Cheung, PhD, MPhil, BN
852 39430515
ankiecheung@cuhk.edu.hk
The Chinese University of Hong Kong
Interventions
  • Behavioral: Mindfulness-based music breathing intervention — Participants in the intervention group will receive a 4-week music plus mindfulness-based breathing program, consisting of one 60-minute face-to-face session per week. The sessions will be delivered in small groups by a qualified music breathing practitioner. The intervention will follow a structured protocol developed by the research team and reviewed by a certified trained music-breathing therapist. Each session will consist of four progressive breathing phases, including: I. Discovery Breathing - to increase awareness of breath and bodily sensations II. Triangular Breathing - to cultivate control and balance through rhythm III. Silent Breathing - to promote stillness and internal reflection IV. Music Breathing - to combine guided music listening with mindful breathing for emotional regulation
  • Behavioral: control group — Participants in the control group will receive usual care, which may include access to existing community-based services, health education, or leisure activities, but will not involve any structured music or mindfulness-based intervention.
Study Locations (1 sites)
The Chinese University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Aged 65 years or above * Able to read Chinese and communicate in Cantonese/Mandarin. * Has mild to moderate anxiety and/or depressive symptoms, based on the - Hospital Anxiety and Depression Scale (HADS) (i.e., a score of 8 or higher on either the anxiety or depression subscale) Exclusion Criteria: * Partcipants will be excluded if they have cognitive impairment, hearing loss, severe depression, known mental illness, or chronic illness.
Conditions Advanced HR+/HER2- Breast Cancer
Phase PHASE1
Enrollment 194
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: IEV407 — Oral administration
  • Drug: Fulvestrant — Intramuscular injection. Approved medication.
  • Drug: Letrozole — Oral administration. Approved medication.

Primary Outcomes

  • Incidence and severity of dose-limiting toxicities (DLTs) (28 days)
  • Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) (Up to approximately 2 years)
  • Frequency of dose interruptions, reductions and discontinuations (Up to approximately 2 years)
  • Dose intensity (Up to approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-05-28
Completion: 2032-06-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 194 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
1-888-669-6682
novartis.email@novartis.com
Novartis Pharmaceuticals
+41613241111
Carl Brown
carl.brown@yale.edu
Yale New Haven Hospital
Interventions
  • Drug: IEV407 — Oral administration
  • Drug: Fulvestrant — Intramuscular injection. Approved medication.
  • Drug: Letrozole — Oral administration. Approved medication.
Study Locations (6 sites)
Yale New Haven Hospital, New Haven, Connecticut 06520 United States
Mary Crowley Cancer Research, Dallas, Texas 75251 United States
Novartis Investigative Site, Toronto, Ontario M5G 2M9 Canada
Novartis Investigative Site, Hirakata, Osaka 5731191 Japan
Novartis Investigative Site, Singapore, 119074 Singapore
Novartis Investigative Site, Seoul, Seoul 06351 South Korea
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Patients with one of the following indications: * Dose escalation (IEV407 single agent and in combination with fulvestrant or letrozole): HR+/HER2- aBC with disease progression on or following, or have been intolerant to, at least one line of endocrine-based therapy in combination with a CDK4/6 inhibitor and at least one additional line of systemic therapy in the unresectable/metastatic setting and not be a candidate for any available standard therapy, in the investigator's judgement. \- Dose expansion of IEV407 in combination with fulvestrant: HR+/HER2- aBC with disease progression on or following, or have been intolerant to, endocrine-based therapy in combination with a CDK4/6 inhibitor. They must not have received more than two prior lines of endocrine-based therapy in the unresectable/metastatic setting. Prior cytotoxic chemotherapy and/or antibody-drug conjugate therapies in the unresectable/metastatic setting are not allowed. Exclusion Criteria: * Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values. * Impaired cardiac function or clinically significant cardiac disease. * Concurrent use of hormone replacement therapy. * Women of childbearing potential who are unwilling to use highly effective contraception methods, pregnant or nursing women. * For the combination treatment of IEV407 with fulvestrant or letrozole: Patients with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine-based therapy. Other protocol-defined inclusion/exclusion criteria may apply.
Conditions HER2 + Breast Cancer, Advanced Breast Ca...
Phase PHASE4
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Given that pyrotinib has been proven to exert significant efficacy against HER2-positive advanced breast cancer in multiple Phase III studies, and the novel ADC drug disitamab vedotin has demonstrated potent anti-tumor activity, there remains insufficient real-world data on their sequential administration. This multicenter, prospective real-world study plans to enroll 500 patients with HER2-positive advanced breast cancer receiving first-line or second-line treatment. It aims to evaluate the efficacy and safety of sequential disitamab vedotin treatment after disease progression or intolerance to pyrotinib-based regimens (first-line: pyrotinib plus trastuzumab combined with chemotherapy; second-line: pyrotinib plus capecitabine). The primary endpoint is real-world second progression-free survival (rwPFS2), while secondary endpoints cover real-world progression-free survival (rwPFS), tumor response, overall survival (OS), time to treatment failure, safety profiles and patient-reported outcomes. It is currently expected to further validate the efficacy and safety of pyrotinib in patients with advanced HER2-positive breast cancer in the real-world setting, and to evaluate the efficacy and safety of recindopril trastuzumab following pyrotinib-containing regimens.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib — Pyrotinib: administered orally once daily at a dose of 400 mg, 320 mg or 240 mg within 30 minutes after breakfast. A continuous administration of 21 days is defined as one treatment cycle. The dosage of pyrotinib will be adjusted by physicians according to the individual clinical conditions. Concomitant chemotherapeutic agents and other supportive care treatments are determined at the investigators' discretion in accordance with clinical practice guidelines and drug instructions.
  • Drug: Trastuzumab Rezetecan — Trastuzumab Rezetecan: administered intravenously at a dose of 4.8 mg/kg on Day 1 of each cycle, with a 21-day treatment cycle.

Primary Outcomes

  • rwPFS2 (From the start of first administration of pyrotinib-containing regimen (first-line or second-line) until disease progression or death occurring after the initiation of subsequent trastuzumab Rezetecan therapy,assessed up to 60 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-07-06
Completion: 2031-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University People's Hospital
Principal Investigators:
  • wang shu (STUDY_CHAIR) - Peking University People's Hospital
Contact Information
Study Contact:
peng yuan
86+13671287670
13671287670@163.com
yuan peng
86+13671287670
13671287670@163.com
Peking University People's Hospital
Interventions
  • Drug: Pyrotinib — Pyrotinib: administered orally once daily at a dose of 400 mg, 320 mg or 240 mg within 30 minutes after breakfast. A continuous administration of 21 days is defined as one treatment cycle. The dosage of pyrotinib will be adjusted by physicians according to the individual clinical conditions. Concomitant chemotherapeutic agents and other supportive care treatments are determined at the investigators' discretion in accordance with clinical practice guidelines and drug instructions.
  • Drug: Trastuzumab Rezetecan — Trastuzumab Rezetecan: administered intravenously at a dose of 4.8 mg/kg on Day 1 of each cycle, with a 21-day treatment cycle.
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality 100044 China
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥ 18 years old; 2. Histopathologically confirmed HER2-positive inoperable locally advanced or metastatic breast cancer; 3. Patients with first-line or second-line advanced disease: First-line advanced disease: no prior systemic therapy for locally advanced or metastatic disease. For patients who received neoadjuvant or adjuvant therapy, the disease-free interval (DFI) after the completion of the last chemotherapy or HER2-targeted therapy was more than 12 months; Second-line advanced disease: prior treatment with taxane combined with trastuzumab, with or without pertuzumab, in the advanced setting; or recurrence occurring during neoadjuvant/adjuvant therapy, or a disease-free interval (DFI) of ≤ 12 months after completion of the last neoadjuvant/adjuvant chemotherapy and HER2-targeted therapy; 4. Planned to receive pyrotinib-containing regimen, and judged by investigators based on clinical practice to have potential subsequent treatment with Ruikang trastuzumab after failure of pyrotinib-containing therapy; 5. Traceable medical records available throughout the treatment period. Exclusion Criteria: 1. Failure to sign the informed consent form; 2. Pregnant or lactating females; 3. Patients participating in any interventional clinical trial involving investigational drugs or marketed drugs at enrollment; 4. Other conditions deemed ineligible for enrollment by the investigator's judgment.
Conditions Depression / Major Depressive Disorder, ...
Phase NA
Enrollment 300
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial will test whether providing medically tailored groceries for 6 months can improve depressive symptoms among adults with depression and food insecurity. The intervention under study is a 6-month, medically tailored grocery program provided by the Boston-based non-profit organization, Community Servings. Food boxes are mailed to participants' homes every two weeks and are designed by a registered dietitian nutritionists to support an individuals' health needs. Participants may also attend optional nutritional counseling sessions. In this randomized clinical trial, 300 adults with depression and food insecurity will be assigned to one of two groups. The intervention group will receive medically tailored grocery boxes delivered to their home every two weeks for six months (13 boxes total), along with nutritional counseling support. The comparison group will receive usual medical care plus a $30 monthly grocery gift card for six months to be used to purchase any products of their choice. Participants will be recruited from UMass Memorial Health and health centers associated with Community Care Cooperative (C3) in the greater Worcester area in Massachusetts.The main goal of the study is to determine whether the grocery program reduces symptoms of depression. The study will also examine effects on anxiety, food insecurity, diet quality, and healthcare use.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Medically Tailored, Home-delivered Groceries — 13-box home grocery delivery (1 Welcome Box of pantry and spice staples and 12 grocery boxes) for a six-month intervention period; nutrition and other resources to sustain the benefit of the intervention.
  • Other: Active Comparison Group: Monthly Grocery Gift Card — $30/month food subsidy in the form of gift cards to Amazon or Hannaford grocery stores

Primary Outcomes

  • Depressive Symptoms as measured by Patient Health Questionnaire (PHQ-9) [Time Frame: 6 months] (At baseline and within the last month of the program enrollment (6 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-29
Completion: 2029-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Worcester
Collaborators: Community Servings, Health Foundation of Central Massachusetts
Principal Investigators:
  • Kurt Hager, Phd (PRINCIPAL_INVESTIGATOR) - UMass Chan Medical School
Contact Information
Study Contact:
Kurt Hager, PhD, MS
508-856-3247
Kurt.Hager1@umassmed.edu
Kim Prendergast Vice President, Policy & Strategy at C3, MPP
1-866-676-9226
kprendergast@c3aco.org
Community Care Cooperative (C3)
Kurt Hager Assistant Professor, PhD, MS
(508) 856-8989
kurt.hager1@umassmed.edu
UMass Memorial Health
Interventions
  • Other: Medically Tailored, Home-delivered Groceries — 13-box home grocery delivery (1 Welcome Box of pantry and spice staples and 12 grocery boxes) for a six-month intervention period; nutrition and other resources to sustain the benefit of the intervention.
  • Other: Active Comparison Group: Monthly Grocery Gift Card — $30/month food subsidy in the form of gift cards to Amazon or Hannaford grocery stores
Study Locations (3 sites)
UMass Chan Medical School, Worcester, Massachusetts 01605 United States
Community Care Cooperative (C3), Worcester, Massachusetts 01655 United States
UMass Memorial Health, Worcester, Massachusetts 01655 United States
Eligibility Criteria
Inclusion Criteria: * A depression diagnosis with active symptoms, defined as having a recent Patient Health Questionnaire (PHQ-9) screening of 5+, or no depression diagnosis but a recent PHQ-9 screening of 10+ * Experiencing food insecurity (could be either low or very low food security) * Lives in Central Massachusetts in Worcester County * Receives care at UMass Memorial Health, or receives care at clinics affiliated with Community Care Cooperative (C3) * Can prepare and cook meals independently, or has a family member or caregiver able to prepare food Exclusion Criteria: * Pregnant women and women who are within one year postpartum at baseline. Women who become pregnant during trial will be allowed to finish their food programming and study participation. * New depression diagnosis within the past 3 months * Has bipolar depression or bipolar disorder * Expresses suicide ideation in baseline depression screening defined as responding "nearly everyday" to question #9 in the Patient Health Questionnaire: "Over the last 2 weeks, how often have you been bothered by any of the following problems - Thoughts that you would be better off dead, or of hurting yourself?"